A phase II proof-of-concept study of PST-611 in geographic atrophy (GA)/dry age-related macular degeneration (AMD)
Latest Information Update: 11 Oct 2024
At a glance
- Drugs PST 611 (Primary)
- Indications Dry macular degeneration
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 11 Oct 2024 New trial record
- 07 Oct 2024 According to a PulseSight Therapeutics media release, company is planning to submit a phase I clinical trial authorization (CTA) by end October, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety by end 2027.